Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30545309 | 1.00 | CYP3A4 (0.60) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL26481059 | 0.97 | CYP3A4 (0.54) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL12375248 | 0.93 | CYP3A4 (0.51) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL4133119 | 0.88 | CYP3A4 (0.43) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL26481061 | 0.87 | CYP3A4 (0.71) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL30350587 | 0.87 | CYP3A4 (0.71) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL23327309 | 0.87 | CYP3A4 (0.47) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL2029772 | 0.86 | CYP3A4 (0.78) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL23327127 | 0.85 | CYP3A4 (0.42) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL23327278 | 0.85 | CYP3A4 (0.42) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411036-B1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE INC (TW) | 2021-12-29 | — | — | EP | disclosed |
| US-11116767-B2 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications | PHARMAENGINE, INC. (TW) | 2021-09-14 | — | — | US | disclosed |
| US-20210137918-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | PHARMAENGINE, INC. (TW) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137918-A1 | 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS | CHEK1, CHEK2, BUB1 | CYP3A4 2547/4885USP2 1769/4885MAPK1 337/4885 |
| US-11116767-B2 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (Chk1) inhibitors, and their preparations and applications | CHEK1, CHEK2, BUB1 | CYP3A4 2547/4885USP2 1769/4885MAPK1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.